Links

©Viva Biotech (Shanghai) Ltd. 沪ICP备12042930号   Powerd by 300.cn 

Viva Biotech Collaborates with NanoImaging Services

Classification:
News
Author:
Viva
Source:
Viva
2021/10/13 10:01
[Abstract]:
To Offer an Integrated CryoEM Gene-to-Structure Workflow to Streamline Target Discovery

Shanghai,  San Diego ——  
Viva Biotech Holdings (1873.HK) and NanoImaging Services, Inc. recently announced a new partnership agreement that will provide clients with a streamlined, cryoEM enabled gene to structure workflow.
 
Under the terms of the collaboration, clients can access the pooled resources of both companies under a single agreement to manage their projects from construct design through to final maps and subsequent protein supply and analyses for medicinal chemistry cycles. This will facilitate target and structure validation for companies with challenging targets that lack protein science and/or cryo-EM expertise and infrastructure.
 
“We are very excited to build the strategic cooperation with NIS. Viva and NIS will achieve great synergies. As the world's top cryo-EM service provider, NIS has considerable advantages in technology and equipment. As the world's leading drug discovery platform, Viva has efficient protein purification and production capabilities, along with the advanced membrane protein expression and screening technology. Our cooperation is expected to further enhance the ability of target discovery, to empower the clients to develop new drugs as soon as possible, and benefit more patients.” said Dr. Ren Delin, Executive Director and President of Viva.
 
“By combining forces and aligning already successful and proven workflows, we believe target enablement and medicinal chemistry timelines can be shortened significantly and success rates increased, bringing down the overall investment costs.” said Ben Schenker, Chief Commercial Officer at NanoImaging Services.
 
“It is clear that one of the strongest predictors of success in structural enablement of drug discovery targets is the purity, homogeneity, and in-depth biochemical and biophysical characterization of the reagents involved”, said Giovanna Scapin, Ph.D., Chief Scientific Officer at NIS. “This new collaborative agreement brings together a worldwide leader in protein production and characterization with our industry-leading expertise and innovation in high-resolution structural enablement by cryo-EM. Together we aim to successfully target the most complex and challenging projects in drug discovery for our shared clients in a cost- and time- effective manner.” 


About NanoImaging Services

NIS launched in 2007 to provide imaging services to the pharmaceutical, biotechnology and nanotechnology communities. We have since built a client-focused organization with a reputation for expertise, reliability and collaboration. NIS is committed to expanding our service capacity through microscope acquisition, workflow automation, recruitment and training of top talent, and the development of new service offerings. Our state-of-the-art facilities include a range of electron microscopes, sample preparation equipment and computational infrastructure to support structural biology, nanoparticle characterization and chemistry workflows. With recent acquisitions, NIS has become the largest and most comprehensive provider of TEM, cryoEM and microED services to the industrial life science market.

Visit www.nanoimagingservices.com/about-us/our-company.